KIT and neoplasm: A recent randomized, open-label, phase III study (SSGXVIII/AIO) evaluated adjuvant imatinib therapy for 3 years compared with 1 year in patients with KIT-positive GIST removed by surgery who were at high risk of recurrence (tumor size >100 mm or tumor with a mitotic rate of >10 mitoses/50 HPFs or tumor size >50 mm and a mitotic rate of >5 mitoses/50 HPFs or tumor rupture)[41].